While initial correlative studies had shown a reduction in TAMs and influx of tumor-infiltrating lymphocytes [216], subsequent analyses demonstrated that CCR2 inhibition resulted in compensatory increases in CXCR2+ TANs, putting into question the rationale of targeting a single myeloid subset [217]. This evidence concerns the gene CXCR2 and neoplasm.